← Eichor
Study identifier: NCT06105801 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

Condition: Lung Cancer  ·  Sponsor: Vanderbilt-Ingram Cancer Center

PhasePhase 4
Planned participants250
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multi-center clinical trial evaluating the effect of transbronchial mediastinal cryobiopsy for its ability to improve the likelihood of obtaining tissue sufficient for molecular analysis. Patients in outpatient clinics or pre-operative holding areas planning to undergo a bronchoscopic biopsy of a suspected malignant lesion (peripheral or mediastinal) for initial diagnosis, staging, or tissue acquisition for molecular analysis will be considered for enrollment and consented. Patients will only be enrolled if intraoperative ROSE suggests malignancy. Patients will be randomized to continue with the operator's initial EBUS-TBNA needle or switch to a cryoprobe to perform a sampling.

This description comes directly from the study's public registry record.

Talk to the study team

Vanderbilt-Ingram Services for Timely Access  ·  800-811-8480  ·  cip@vumc.org

Always discuss trial participation with your own doctor first.

Locations (1)

Vanderbilt University/Ingram Cancer CenterNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06105801